Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 86


Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassification.

Boyd A, Maylin S, Moh R, Gabillard D, Menan H, Mahjoub N, Danel C, Anglaret X, Eholié SP, Girard PM, Zoulim F, Delaugerre C, Lacombe K; ANRS 12240 VarBVA study.

Diagn Microbiol Infect Dis. 2015 Jul 18. pii: S0732-8893(15)00235-7. doi: 10.1016/j.diagmicrobio.2015.07.009. [Epub ahead of print]


Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe.

Ozaras R, Corti G, Ruta S, Lacombe K, Mondelli MU, Irwing WL, Puoti M, Khalighi A, Santos ML, Harxhi A, Lazarevic I, Soriano V, Gervain J, Leblebicioglu H, Salmon D, Arends JE; ESCMID Study Group for Viral Hepatitis.

Clin Microbiol Infect. 2015 Jul 10. pii: S1198-743X(15)00692-8. doi: 10.1016/j.cmi.2015.07.002. [Epub ahead of print]


Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.

Boyd A, Gozlan J, Miailhes P, Lascoux-Combe C, Cam MS, Rougier H, Zoulim F, Girard PM, Lacombe K.

AIDS. 2015 Jul 4. [Epub ahead of print]


Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study.

Leprêtre A, Ba I, Lacombe K, Maynart M, Toufik A, Ndiaye O, Kane CT, Gozlan J, Tine J, Ndoye I, Raguin G, Girard PM.

J Int AIDS Soc. 2015 May 22;18:19888. doi: 10.7448/IAS.18.1.19888. eCollection 2015.


High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.

Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS HC30 QUADRIH Study Group.

Clin Infect Dis. 2015 Sep 1;61(5):817-25. doi: 10.1093/cid/civ381. Epub 2015 May 14.


Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals.

Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord.

AIDS. 2015 Jun 19;29(10):1205-15. doi: 10.1097/QAD.0000000000000674.


Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV co-infected patients from Côte d'Ivoire.

Boyd A, Moh R, Gabillard D, le Carrou J, Danel C, Anglaret X, Eholie SP, Maylin S, Delaugerre C, Zoulim F, Girard PM, Lacombe K; ANRS 12240 VarBVA study.

Antivir Ther. 2015 Apr 8. doi: 10.3851/IMP2959. [Epub ahead of print]


Metabolic disorders and cardiovascular risk in treatment-naive HIV-infected patients of sub-saharan origin starting antiretrovirals: impact of westernized lifestyle.

Eholié SP, Lacombe K, Krain A, Diallo Z, Ouiminga M, Campa P, Bouchaud O, Bissagnene E, Girard PM.

AIDS Res Hum Retroviruses. 2015 Apr;31(4):384-92. doi: 10.1089/AID.2014.0164. Epub 2015 Mar 17.


Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure.

Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F.

Gut. 2015 Aug;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943. Epub 2015 Feb 10. Review.


Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.

Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, Sogni P, Fontaine H, Rosenthal E, Winnock M, Loko MA, Wittkop L, Dabis F, Salmon D; ESCMID European Study Group on Viral Hepatitis.

Liver Int. 2015 Sep;35(9):2090-9. doi: 10.1111/liv.12799. Epub 2015 Feb 23.


Telaprevir enhances ribavirin-induced anaemia through renal function impairment.

Cotte L, Barrail-Tran A, Vincent C, Valantin MA, Fournier I, Lacombe K, Chevaliez S, Aboulker JP, Taburet AM, Molina JM; ANRS HC26 study group.

Antivir Ther. 2015 Jan 6. doi: 10.3851/IMP2929. [Epub ahead of print]


Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.

Piroth L, Pol S, Miailhes P, Lacombe K, Lopes A, Fillion A, Loustaud-Ratti V, Borsa-Lebas F, Salmon D, Rosenthal E, Carrat F, Cacoub P; GERMIVIC Study Group.

Liver Int. 2015 Aug;35(8):1950-8. doi: 10.1111/liv.12777. Epub 2015 Jan 22.


Molecular epidemiology of human rhinovirus infections in the pediatric emergency department.

Martin EK, Kuypers J, Chu HY, Lacombe K, Qin X, Strelitz B, Bradford M, Jones C, Klein EJ, Englund JA.

J Clin Virol. 2015 Jan;62:25-31. doi: 10.1016/j.jcv.2014.11.006. Epub 2014 Nov 15.


Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach.

Lemoine M, Eholié S, Lacombe K.

J Hepatol. 2015 Feb;62(2):469-76. doi: 10.1016/j.jhep.2014.10.008. Epub 2014 Oct 16. Review.


Hepatitis C, from screening to treatment, a revolution.

Lacombe K.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19499. doi: 10.7448/IAS.17.4.19499. eCollection 2014.


Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010.

Geri G, Maynard M, Rosenthal E, Fontaine H, Lacombe K, Slama L, Goujard C, Loustaud-Ratti V, Bergmann JF, Morlat P, Vittecoq D, Alric L, Cacoub P; GERMIVIC Group.

Liver Int. 2014 Oct;34(9):1349-57.


Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.

Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group.

Clin Infect Dis. 2014 Dec 15;59(12):1768-76. doi: 10.1093/cid/ciu659. Epub 2014 Aug 18.


Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.

Boyd A, Gozlan J, Maylin S, Delaugerre C, Peytavin G, Girard PM, Zoulim F, Lacombe K.

Hepatology. 2014 Aug;60(2):497-507. doi: 10.1002/hep.27182. Epub 2014 Jun 20.


Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region.

Bottero J, Boyd A, Lemoine M, Carrat F, Gozlan J, Collignon A, Boo N, Dhotte P, Varsat B, Muller G, Cha O, Valin N, Nau J, Campa P, Silbermann B, Bary M, Girard PM, Lacombe K.

PLoS One. 2014 Mar 24;9(3):e92266. doi: 10.1371/journal.pone.0092266. eCollection 2014.


Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.

Boyd A, Maylin S, Gozlan J, Delaugerre C, Simon F, Girard PM, Lacombe K.

Liver Int. 2015 Mar;35(3):795-804. doi: 10.1111/liv.12521. Epub 2014 Mar 31.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk